Eagle Asset Management Inc. Invests $3.95 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

Eagle Asset Management Inc. bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 168,795 shares of the biopharmaceutical company’s stock, valued at approximately $3,948,000. Eagle Asset Management Inc. owned about 0.11% of TG Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. NBC Securities Inc. lifted its position in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of TG Therapeutics in the second quarter valued at about $35,000. ORG Wealth Partners LLC bought a new stake in shares of TG Therapeutics in the third quarter valued at about $53,000. Finally, Values First Advisors Inc. bought a new stake in shares of TG Therapeutics in the third quarter valued at about $58,000. 58.58% of the stock is currently owned by institutional investors.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TGTX has been the subject of several recent research reports. HC Wainwright lifted their price objective on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. B. Riley boosted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. TD Cowen initiated coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. Finally, The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.67.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $35.07 on Monday. TG Therapeutics, Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $36.50. The firm has a market capitalization of $5.46 billion, a price-to-earnings ratio of -350.66 and a beta of 2.19. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock’s 50-day simple moving average is $25.62 and its 200-day simple moving average is $21.70.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter in the previous year, the firm posted $0.73 EPS. TG Therapeutics’s revenue was down 49.4% on a year-over-year basis. As a group, equities analysts forecast that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.